These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33771522)

  • 41. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
    Yu L; Chen D; Song J
    Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiR-323-3p Targeting Transmembrane Protein with EGF-Like and 2 Follistatin Domain (TMEFF2) Inhibits Human Lung Cancer A549 Cell Apoptosis by Regulation of AKT and ERK Signaling Pathways.
    Fan JM; Zheng ZR; Zeng YM; Chen XY
    Med Sci Monit; 2020 Feb; 26():e919454. PubMed ID: 32009129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
    Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
    Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
    Dong Z; Liu H; Zhao G
    Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
    [No Abstract]   [Full Text] [Related]  

  • 48. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.
    Zhong Y; Lin H; Li Q; Liu C; Shen J
    Cancer Biomark; 2021; 30(2):261-273. PubMed ID: 33682697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.
    Tian W; Yang X; Yang H; Lv M; Sun X; Zhou B
    Cell Death Dis; 2021 Oct; 12(11):1030. PubMed ID: 34718336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MiroRNA-31-3p Promotes the Invasion and Metastasis of Non-Small-Cell Lung Cancer Cells by Targeting Forkhead Box 1 (FOXO1).
    Zeng X; Liu D; Peng G; Liu J; Yang H
    Comput Math Methods Med; 2022; 2022():4597087. PubMed ID: 35126623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
    BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
    Chen S; Zhang Z; Zhang J
    Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
    [No Abstract]   [Full Text] [Related]  

  • 55. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
    Liu YY; Zhang LY; Du WZ
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
    Li X; Han X; Wei P; Yang J; Sun J
    Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non-small cell lung cancer via positively modulating KPNA4 by sponging miR-1298-5p.
    Hu S; Zhang Q; Sun J; Xue J; Wang C
    Thorac Cancer; 2023 Aug; 14(22):2116-2126. PubMed ID: 37455373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.
    Fan Q; Hu X; Zhang H; Wang S; Zhang H; You C; Zhang CY; Liang H; Chen X; Ba Y
    Cell Physiol Biochem; 2017; 44(4):1311-1324. PubMed ID: 29183007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-103 Functions as a Tumor Suppressor by Directly Targeting Programmed Cell Death 10 in NSCLC.
    Yang D; Wang JJ; Li JS; Xu QY
    Oncol Res; 2018 May; 26(4):519-528. PubMed ID: 28734041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.